BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, May 4, 2024
See today's BioWorld
Home
» Celltrion's Inflectra coming to U.S.; Pfizer prepping for launch
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Celltrion's Inflectra coming to U.S.; Pfizer prepping for launch
Oct. 19, 2016
By
Haky Moon
No Comments
HONG KONG – South Korean drugmaker Celltrion Inc.'s Inflectra (infliximab-dyyb) will begin shipments to the U.S. by late November, making it the first biosimilar monoclonal antibody marketed in the U.S.
BioWorld